<DOC>
	<DOCNO>NCT01508923</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial determine effect NNC 90-1170 ( liraglutide ) glucose hormonal profile , fast gluconeogenesis insulin secretion subject type 2 diabetes .</brief_summary>
	<brief_title>Effect Liraglutide Glucose Profiles Gastric Emptying Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes mellitus Diet treat and/or subject monotherapy max . 50 % maximal dose sulphonylurea ( SU ) . In addition , subject treatment metformin and/or repaglinide could include Body Mass Index ( BMI ) maximum 35 kg/m^2 Fasting plasma glucose 715 mmol/l , inclusive Impaired liver function Impaired renal function Anaemia Cardiac disease Uncontrolled treated/untreated hypertension Recurrent major hypoglycaemia judge Investigator Known suspect allergy trial product relate product Females child bear potential pregnant , breastfeed intention become pregnant use adequate contraceptive measure Current treatment thiazolidinediones chronic daily use insulin ( 7 day ) within three month absence intercurrent illness Loss 400 ml blood three month prior study start Allergy paracetamol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>